| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $0 ) |
| | 2026 | 2024 | NEMALIFE INC | 3911 4TH ST | LUBBOCK | TX | 79409-9805 | LUBBOCK | USA | R43AA031342 | Development of an AI-assisted therapeutic discovery platform for Alcohol Use Disorders using an invertebrate model | 000 | 1 | NIH | 12/4/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $617,850 ) |
| | 2024 | 2024 | NEMALIFE INC | 3911 4TH ST | LUBBOCK | TX | 79409-9805 | LUBBOCK | USA | R43AA031342 | Development of an AI-assisted therapeutic discovery platform for Alcohol Use Disorders using an invertebrate model | 001 | 1 | NIH | 3/15/2024 | $32,207 |
| | 2024 | 2024 | NEMALIFE INC | 3911 4TH ST | LUBBOCK | TX | 79409-9805 | LUBBOCK | USA | R43AA031342 | Development of an AI-assisted therapeutic discovery platform for Alcohol Use Disorders using an invertebrate model | 000 | 1 | NIH | 2/29/2024 | $289,863 |
| | 2024 | 2024 | NEMALIFE INC | 3911 4TH ST | LUBBOCK | TX | 79409-9805 | LUBBOCK | USA | R43AT012449 | Development of a high throughput in vivo screening platform for identifying novel pro-and postbiotic bacterial strains | 000 | 1 | NIH | 9/17/2024 | $295,780 |
| | 2024 | 2022 | NEMALIFE INC | 3911 4TH ST | LUBBOCK | TX | 79409-9805 | LUBBOCK | USA | R43AG078715 | High throughput functional screening of anti-sarcopenia therapeutics | 000 | 1 | NIH | 4/10/2024 | $0 |
| | 2024 | 2022 | NEMALIFE INC | 3911 4TH ST | LUBBOCK | TX | 79409-9805 | LUBBOCK | USA | R43DA056089 | AI-assisted behavioral profiling of an invertebrate model to identify new psychedelic therapeutics for stimulant use disorders | 000 | 1 | NIH | 3/4/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | NEMALIFE INC | 3911 4TH ST | LUBBOCK | TX | 79409-9805 | LUBBOCK | USA | R43ES032516 | A novel technology to assess chronic toxicity in genetically diverse nematode populations | 001 | 1 | NIH | 5/16/2023 | $0 |
| | 2023 | 2021 | NEMALIFE INC | 3911 4TH ST | LUBBOCK | TX | 79409-9805 | LUBBOCK | USA | R43ES032516 | A novel technology to assess chronic toxicity in genetically diverse nematode populations | 000 | 1 | NIH | 5/15/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $716,392 ) |
| | 2022 | 2022 | NEMALIFE INC. | 3911 4TH ST | LUBBOCK | TX | 79409-9805 | LUBBOCK | USA | R43DA056089 | AI-assisted behavioral profiling of an invertebrate model to identify new psychedelic therapeutics for stimulant use disorders | 000 | 1 | NIH | 3/4/2022 | $318,373 |
| | 2022 | 2022 | NEMALIFE INC. | 3911 4TH ST | LUBBOCK | TX | 79409-9805 | LUBBOCK | USA | R43AG078715 | High throughput functional screening of anti-sarcopenia therapeutics | 000 | 1 | NIH | 8/12/2022 | $398,019 |
| | 2022 | 2021 | NEMALIFE INC | 3911 4TH ST | LUBBOCK | TX | 79409-9805 | LUBBOCK | USA | R43AG071142 | High-throughput testing of anti-aging and FDA approved drugs in genetically diverse invertebrate Alzheimer's models | 000 | 1 | NIH | 8/18/2022 | $0 |
| | 2022 | 2021 | NEMALIFE INC. | 3911 4TH ST | LUBBOCK | TX | 79409-9805 | LUBBOCK | USA | R43ES032516 | A novel technology to assess chronic toxicity in genetically diverse nematode populations | 000 | 1 | NIH | 12/2/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $599,325 ) |
| | 2021 | 2021 | NEMALIFE INC. | 3911 4TH ST | LUBBOCK | TX | 79409-9805 | LUBBOCK | USA | R43AG071142 | High-throughput testing of anti-aging and FDA approved drugs in genetically diverse invertebrate Alzheimer's models | 000 | 1 | NIH | 1/5/2021 | $348,285 |
| | 2021 | 2021 | NEMALIFE INC. | 3911 4TH ST | LUBBOCK | TX | 79409-9805 | LUBBOCK | USA | R43ES032516 | A novel technology to assess chronic toxicity in genetically diverse nematode populations | 000 | 1 | NIH | 2/11/2021 | $251,040 |
| | 2021 | 2021 | NEMALIFE INC. | 3911 4TH ST | LUBBOCK | TX | 79409-9805 | LUBBOCK | USA | R43AG071142 | High-throughput testing of anti-aging and FDA approved drugs in genetically diverse invertebrate Alzheimer's models | 001 | 1 | NIH | 1/14/2021 | $0 |
|
|
